The New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy

Results from Three Studies Show Medtronic Cryoablation is Superior to Drug Therapy for First-Line Treatment DUBLIN, Nov. 16, 2020 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the primary results of the Medtronic-sponsored STOP AF First clinical trial have been published in the New England […]

Zio by iRhythm Detects Previously Undiagnosed Atrial Fibrillation and Helps to Prevent Hospitalizations, Stroke, and Death as a Result

Three-Year Study Results Presented at 2020 American Heart Association Scientific Sessions Zio Supports Better Healthcare Utilization Rates and Patient Outcomes With Ambulatory Cardiac Monitoring SAN FRANCISCO, Nov. 16, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, […]

InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020

Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Provides Roadmap for Start of Pivotal Phase 3 in Medically Supervised Setting in 2021 SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a […]

iRhythm Technologies Announces Data from mSToPS Clinical Trial to be Presented in a Late-Breaking Scientific Session at American Heart Association 2020

iRhythm to Host Webcast to Discuss Outcomes on Monday, November 16, 2020 SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that 3-year clinical outcomes in a nationwide, randomized, pragmatic […]

Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions

– Treatment with sotatercept in the ongoing PULSAR Phase 2 trial was associated with improvements in cardiac and pulmonary function at week 24 – – Presentation of echocardiography data from the PULSAR trial received AHA’s “Cardiopulmonary Best Abstract” Award – – Preclinical research shows sotatercept inhibits cardiac remodeling, restores function […]

Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension

− Patients Receiving Investigational ALN-AGT Experienced Dose-Dependent Reductions in Blood Pressure, Confirming Potential for RNAi-Mediated Angiotensinogen (AGT) Silencing as a Novel Therapeutic Approach for Hypertension – − Durable AGT Knockdown Through 12 Weeks Supports a Once Quarterly or Potentially Less Frequent Dosing Regimen – − ALN-AGT Generally Well Tolerated, with […]

UNC Medical Center First in the Carolinas to Treat Heart Failure Patients Using Breakthrough CCM Therapy

Innovative minimally-invasive therapy is proven to help people with heart failure feel better CHAPEL HILL, N.C.–(BUSINESS WIRE)–UNC Medical Center today announced it is among the first hospitals in the United States and the first hospital in the Carolinas to use CCM® therapy, delivered by the Optimizer® system, to treat patients suffering from heart failure. […]

CB Scientific, Inc. (CBSC) Announces Definitive Agreement to Acquire Commercial Ambulatory ECG Device Manufacturer Datrix, LLC

Acquisition will expand Ambulatory Remote Cardiac ECG Monitoring product technology offering and outreach into US and international markets ESCONDIDO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — via InvestorWire – CB Scientific. Inc. (OTC:CBSC) (“CBSC” or the “Company”), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring […]

Nanowear Receives FDA 510(k) Clearance for SimpleSENSE, a Cloth-Based Wearable Remote Diagnostic Monitoring Platform

SimpleSENSE provides a continuous, simultaneous, and synchronous assessment of the heart, lungs, and upper vascular system without the need for an in-person doctor’s visit NEW YORK, Nov. 11, 2020 /PRNewswire/ — Nanowear www.nanowearinc.com, the leading connected-care and remote diagnostic platform, today announced it has received FDA Class II 510(k) clearance for a first-of-its-kind cloth-based […]